More than 1,400 registered in the first virtual congress of the Spanish Diabetes Society
–
June 19, 2020. 4:28 pm
–
Diabetes monitoring and Precision Medicine are some of the most notable advances that have occurred in recent months. Together with COVID-19, they will be the main topics to be addressed at the first virtual congress of the Spanish Society of Diabetes (THIRST). This meeting will be held from June 21-23, replacing the XXXI National Congress which was to be held in person in Madrid.
“COVID-19 has become a promoter of mortality from cardiovascular disease and diabetes,” they have reviewed from the SED. For this reason, the pandemic has been incorporated into its program, which will also be the main theme of the closing conference that Fernando Rodríguez Artalejo will offer.
As they have commented in the presentation of the congress, practically all the scientific program initially planned is maintained. Antonio Pérez Pérez, new president of the SED, It has confirmed that the virtual meeting will have the participation of more than 1,400 people, who have already registered, as well as a high number of collaborating companies. Regarding the content of the congress, he highlighted “the steps that are being taken in precision medicine”. “More and more we have tools that allow us to better identify the population, with phenotypic and genotypic studies. Therefore, we will be able to carry out actions and propose more targeted treatments for each patient ”.
Two congresses
Alfonso Calle Pascual, President of the Organizing Committee, He explained the difficulty of organizing “two conferences”. He has also expressed his regret at not being able to enjoy “a city as friendly as Madrid”.
For his part, Juan Francisco Merino, president of the Scientific Committee of this Congress, has listed the main topics to be addressed at the meeting, apart from COVID-19.
- The genomic risk in diabetes.
- The role of ectopic fat.
- The regression of diabetes with lifestyle modifications.
- The artificial pancreas.
- The new antidiabetics with cardio and nephroprotective effects.
- The residual risk in DM2.
- The link of cognitive decline and diabetes.
Drugs and Nephroprotectors
Experts have also discussed therapeutic novelties, among which Juan Francisco Merino has highlighted cardio and nephroprotective drugs and sodium-glucose cotransporter inhibitors (SGLT). “The clinical practice guidelines are already reflecting this: today it is not conceivable to initiate or modify a treatment for diabetes without taking into account the impacts of the therapy on patient complications. “These new drugs have come to revolutionize the vademecum of type 2 diabetes. This is what the guidelines are collecting and it has also been discussed at the recent American Diabetes Congress.”
–
